Neurology & Psychiatry · LP-156
Risperidone Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-156Neurology & Psychiatry
- Generic identity
- RisperidoneTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-156
- Generic ingredient
- Risperidone
- Dosage form
- Tablet
- Proposed strength
- 1 mg; 2 mg; 4 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
About Risperidone
Risperidone is an antipsychotic medicine that affects dopamine and serotonin signalling. It is used for selected psychiatric conditions following diagnosis and monitoring. Oral tablets are distinct from risperidone long-acting injections, whose administration and release characteristics differ. The ingredient name and tablet strengths do not establish suitability for a particular behaviour, age group or care setting.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional assessment may concern schizophrenia, bipolar mania or another indication specifically recognized in the relevant local label. Treatment planning includes patient goals, monitoring of mental state and physical health, and a review of non-drug and supportive care. Use for behavioural symptoms in dementia has important limitations and should not be implied by a broad catalogue category. This page is ingredient education and does not present a complete psychiatric treatment pathway.
Important safety considerations
Weight gain, metabolic changes, sedation, postural hypotension and increased prolactin can occur. Movement disorders, including tardive dyskinesia, and neuroleptic malignant syndrome are serious concerns. Antipsychotics carry increased mortality and cerebrovascular risks in older adults with dementia. Review diabetes, cardiovascular disease, seizure risk and interacting medicines. Fever with rigidity, altered consciousness or severe abnormal movements requires urgent clinical assessment. Medication changes should be supervised.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This record covers conventional oral tablets. It does not establish that they are orally disintegrating or suitable for crushing. The exact tablet type, excipients and strength must be matched to the approved product information and prescription.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review the psychiatric diagnosis, metabolic and cardiovascular baseline, movement symptoms, prolactin-related effects and other medicines. Confirm indication-specific eligibility and follow-up.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Risperidone
- Dosage form / presentation
- Tablet
- Catalogue strength
- 1 mg; 2 mg; 4 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Neurology & Psychiatry
Layer 02
Unresolved product-specific fields
- The catalogue lists conventional tablets at 1 mg, 2 mg and 4 mg. It does not establish orally-disintegrating character, scoring, crushing suitability or excipient equivalence to any comparator.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Risperidonegovernment-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming exact active chemical form, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-156, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-156.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.